相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapies in Parkinson's disease
Joseph Jankovic et al.
CURRENT OPINION IN NEUROLOGY (2012)
Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53
Stefania Girotto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease
Margaret Chia-Ying Wey et al.
PLOS ONE (2012)
Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinson's Disease
Elisa Belluzzi et al.
PLOS ONE (2012)
Parkinsonism Due to Mutations in PINK1, Parkin, and DJ-1 and Oxidative Stress and Mitochondrial Pathways
Mark R. Cookson
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system
David W. Anderson et al.
BRAIN RESEARCH (2011)
Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease
Yunden Jinsmaa et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2011)
Molecular Mechanisms of PINK1-Related Neurodegeneration
Joe H. Pogson et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2011)
Catechols in post-mortem brain of patients with Parkinson disease
D. S. Goldstein et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
Joseph Jankovic et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission
David Sulzer
NEURON (2011)
MAO-inhibitors in Parkinson's Disease
Peter Riederer et al.
Experimental Neurobiology (2011)
Dopamine quinones interact with a-synuclein to form unstructured adducts
Marco Bisaglia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Gene Therapy in Parkinson's Disease Rationale and Current Status
Li Rebekah Feng et al.
CNS DRUGS (2010)
A Rare Novel Deletion of the Tyrosine Hydroxylase Gene in Parkinson Disease
Gueney Bademci et al.
HUMAN MUTATION (2010)
Dopamine Transporter Genetic Variants and Pesticides in Parkinson's Disease
Beate R. Ritz et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2009)
Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease
Domingo Afonso-Oramas et al.
NEUROBIOLOGY OF DISEASE (2009)
New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy
Robert A. Hauser
PARKINSONISM & RELATED DISORDERS (2009)
Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
Bechir Jarraya et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and clinical grade production
Ronald J. Mandel et al.
EXPERIMENTAL NEUROLOGY (2008)
Direct Binding of GTP Cyclohydrolase and Tyrosine Hydroxylase REGULATORY INTERACTIONS BETWEEN KEY ENZYMES IN DOPAMINE BIOSYNTHESIS
Kevin M. Bowling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Altered vesicular dopamine storage in Parkinson's disease: a premature demise
W. Michael Caudle et al.
TRENDS IN NEUROSCIENCES (2008)
Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels
Sandra Vergo et al.
BRAIN RESEARCH (2007)
Epidemiologic studies of environmental exposures in Parkinson's disease
Alexis Elbaz et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration
W. Michael Caudle et al.
JOURNAL OF NEUROSCIENCE (2007)
Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: The role of aldehyde dehydrogenase
Satori A. Marchitti et al.
PHARMACOLOGICAL REVIEWS (2007)
Kinetic and structural analysis of the early oxidation products of dopamine -: Analysis of the interactions with α-synuclein
Marco Bisaglia et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease
Maria Joao Bonifacio et al.
CNS DRUG REVIEWS (2007)
5′ and 3′ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk:: a hypothesis-generating study
Samir N. P. Kelada et al.
HUMAN MOLECULAR GENETICS (2006)
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC
Krystof S. Bankiewicz et al.
MOLECULAR THERAPY (2006)
The therapeutic potential of monoamine oxidase inhibitors
MBH Youdim et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease
HJ Choi et al.
NEUROCHEMISTRY INTERNATIONAL (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys
MM Daadi et al.
NEUROREPORT (2006)
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women
CE Glatt et al.
HUMAN MOLECULAR GENETICS (2006)
The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: Relevance to the dopaminergic pathogenesis
WS Yang et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2005)
Paraquat neurotoxicity is distinct from that of MPTP and rotenone
JR Richardson et al.
TOXICOLOGICAL SCIENCES (2005)
Dopamine covalently modifies and functionally inactivates parkin
MJ LaVoie et al.
NATURE MEDICINE (2005)
Midbrain dopamine and prefrontal function in humans:: interaction and modulation by COMT genotype
A Meyer-Lindenberg et al.
NATURE NEUROSCIENCE (2005)
Dopaminergic neurons
SJ Chinta et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease
HJ Choi et al.
NEUROCHEMISTRY INTERNATIONAL (2005)
The vesicular amine transporter family (SLC18):: amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine
LE Eiden et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
Catecholamine metabolism: A contemporary view with implications for physiology and medicine
G Eisenhofer et al.
PHARMACOLOGICAL REVIEWS (2004)
Evidence of oxidative stress in the circulation of ovarian cancer patients
K Senthil et al.
CLINICA CHIMICA ACTA (2004)
Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration
JG Truong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia
D Galter et al.
NEUROBIOLOGY OF DISEASE (2003)
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration
JG Truong et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Clinical-pathological study of levodopa complications
AH Rajput et al.
MOVEMENT DISORDERS (2002)
Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism
KA Mooslehner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Dope-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations
Y Furukawa et al.
NEUROLOGY (2001)
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease
Y Shen et al.
HUMAN GENE THERAPY (2000)
分享论文
